Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 after Oral Administration
Study identifier:D3030C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2009-010702-11
CTIS identifier:N/A
Study Complete
Official Title
An Open-label Positron Emission Tomography Study to Evaluate Use of Histamine H3 Receptor Radioligand [11C]AZ12807110 and to Determine Histamine H3 Receptor Occupancy of AZD5213 after Oral Administration to Healthy Volunteers
Medical condition
Brain distribution of [11C]AZ12807110 and AZD5213
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD5213
Sex
Female
Actual Enrollment
13
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Nov 2010
Primary Completion Date: 01 Jun 2011
Study Completion Date: 01 Jun 2011
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Pilot panel [11C]AZ12807110 distribution and kinetics | Other: [11C]AZ12807110 Radioligand |
| Experimental: Main panel Histamine receptor occupancy reached by AZD5213 | Other: [11C]AZ12807110 Radioligand |
Contacts
Investigators
Principal Investigator
Björn Paulsson
AstraZeneca
